Combined structure- and ligand-based approach for the identification of inhibitors of AcrAB-TolC in Escherichia coli
Files
(Published version)
Date
2023
Authors
Pisoni, L.A.
Semple, S.J.
Liu, S.
Sykes, M.J.
Venter, H.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
ACS Infectious Diseases, 2023; 9(12):2504-2522
Statement of Responsibility
Conference Name
Abstract
The inhibition of efflux pumps is a promising approach to combating multidrug-resistant bacteria. We have developed a combined structure- and ligand-based model, using OpenEye software, for the identification of inhibitors of AcrB, the inner membrane protein component of the AcrAB-TolC efflux pump in Escherichia coli. From a database of 1391 FDA-approved drugs, 23 compounds were selected to test for efflux inhibition in E. coli. Seven compounds, including ivacaftor (25), butenafine (19), naftifine (27), pimozide (30), thioridazine (35), trifluoperazine (37), and meloxicam (26), enhanced the activity of at least one antimicrobial substrate and inhibited the efflux pump-mediated removal of the substrate Nile Red from cells. Ivacaftor (25) inhibited efflux dose dependently, had no effect on an E. coli strain with genomic deletion of the gene encoding AcrB, and did not damage the bacterial outer membrane. In the presence of a sub-minimum inhibitory concentration (MIC) of the outer membrane permeabilizer colistin, ivacaftor at 1 μg/mL reduced the MICs of erythromycin and minocycline by 4- to 8-fold. The identification of seven potential AcrB inhibitors shows the merits of a combined structure- and ligand-based approach to virtual screening.
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supporting Information, https://doi.org/10.1021/acsinfecdis.3c00350
Access Status
Rights
Copyright 2023 American Chemical Society
Access Condition Notes: Accepted manuscript available after 1 January 2025